3/26
04:12 pm
imnm
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates [Yahoo! Finance]
Medium
Report
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates [Yahoo! Finance]
3/20
11:06 am
imnm
Immunome, Inc. (NASDAQ: IMNM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
Low
Report
Immunome, Inc. (NASDAQ: IMNM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
3/20
09:58 am
imnm
Immunome, Inc. (NASDAQ: IMNM) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $30.00 price target on the stock.
Low
Report
Immunome, Inc. (NASDAQ: IMNM) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $30.00 price target on the stock.
3/20
09:37 am
imnm
Immunome, Inc. (NASDAQ: IMNM) had its price target lowered by analysts at Guggenheim from $35.00 to $25.00. They now have a "buy" rating on the stock.
Low
Report
Immunome, Inc. (NASDAQ: IMNM) had its price target lowered by analysts at Guggenheim from $35.00 to $25.00. They now have a "buy" rating on the stock.
3/19
04:05 pm
imnm
Immunome Reports Full Year 2024 Financial Results and Provides Business Update
Low
Report
Immunome Reports Full Year 2024 Financial Results and Provides Business Update
3/11
08:56 am
imnm
Immunome, Inc. (NASDAQ: IMNM) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $20.00 price target on the stock.
Medium
Report
Immunome, Inc. (NASDAQ: IMNM) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $20.00 price target on the stock.
3/10
12:14 pm
imnm
Immunome, Inc. (NASDAQ: IMNM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
Low
Report
Immunome, Inc. (NASDAQ: IMNM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
3/10
07:59 am
imnm
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC [Yahoo! Finance]
Medium
Report
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC [Yahoo! Finance]
11/13/2024
04:05 pm
imnm
immunome, inc.
MISS
Report
-3.9%
immunome, inc.
8/12/2024
04:01 pm
imnm
immunome, inc.
MISS
Report
7.0%
immunome, inc.
8/12/2024
04:01 pm
imnm
immunome, inc.
MISS
Report
7.0%
immunome, inc.
8/12/2024
04:01 pm
imnm
immunome, inc.
MISS
Report
2.2%
immunome, inc.
3/28
05:54 pm
imnm
Form 4 Immunome Inc. For: Mar 27 Filed by: Higgins Jack
Medium
Report
Form 4 Immunome Inc. For: Mar 27 Filed by: Higgins Jack
3/26
04:05 pm
imnm
Form 4 Immunome Inc. For: Mar 25 Filed by: BIENAIME JEAN JACQUES
Low
Report
Form 4 Immunome Inc. For: Mar 25 Filed by: BIENAIME JEAN JACQUES
3/26
04:03 pm
imnm
Form 4 Immunome Inc. For: Mar 26 Filed by: SIEGALL CLAY B
Low
Report
Form 4 Immunome Inc. For: Mar 26 Filed by: SIEGALL CLAY B
3/25
05:18 pm
imnm
Form 4 Immunome Inc. For: Mar 24 Filed by: BIENAIME JEAN JACQUES
Low
Report
Form 4 Immunome Inc. For: Mar 24 Filed by: BIENAIME JEAN JACQUES
3/25
05:16 pm
imnm
Form 4 Immunome Inc. For: Mar 24 Filed by: Tsai Philip
Low
Report
Form 4 Immunome Inc. For: Mar 24 Filed by: Tsai Philip
3/19
05:10 pm
imnm
Form S-8 Immunome Inc.
Neutral
Report
Form S-8 Immunome Inc.
3/19
04:12 pm
imnm
Form 10-K Immunome Inc. For: Dec 31
Low
Report
Form 10-K Immunome Inc. For: Dec 31
3/19
04:09 pm
imnm
Form 8-K Immunome Inc. For: Mar 19
Low
Report
Form 8-K Immunome Inc. For: Mar 19
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register